COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,219 Articles (22,733 medRxiv, 8,486 bioRxiv)

Most recent first Previous |  Page 44: Articles 431-440  | Next

Predicting interactions between the SARS-CoV-2 spike glycoprotein and the human proteome using AphaFold and molecular dynamics simulations
Liu, Q., Henderson, M.
10.1101/2025.07.28.667129 — Posted: 2025-07-28
SIMPLICITY: an agent-based, multi-scale mathematical model to study SARS-CoV-2 intra- and between-host evolution.
Gerletti, P., Gubela, N., Escudie, J.-B., Kuehnert, D., Von Kleist, M.
10.1101/2025.07.28.667187 — Posted: 2025-07-28
The geospatial phylodynamics of SARS-CoV-2 in Nepal and clinical phenotype of long COVID during the Delta-Omicron waves
Wirth, W., Thomson, T. N., Manandhar, P., Shrestha, S., Napit, R., Dixit, S. M., Shrestha, G., Lane, C. R., Gyanwali, P., Pant, S., Center for Molecular Dynamics Nepal, , Rajbhandari, S. K., Bhandari, P., Chalise, B. S., Das, C. L., Yadav, P. K., Thapa, P., Mishra, P., Basnyat, B., Karkey, A., Maharjan, N., Kovalenko, G., Goodfellow, I., Baker, S., Ioannidis, L. J., Seemann, T., Dunstan, S., Pandey, D., Parajuli, R., Koirala, R. P., Dhital, R., Caws, M.
10.1101/2025.07.24.25332179 — Posted: 2025-07-25
Fewer flights and lower community noise: Noise monitoring at six airports in the United States before, during, and after the COVID-19 pandemic
Seto, E., Huang, C.-H. S.
10.1101/2025.07.25.25332225 — Posted: 2025-07-25
Omicron Subvariants Infection Kinetics and Nirmatrelvir Efficacy in Transgenic K18-hACE2 Mice
Vijeta, S., Dolgov, E., Tillery, T., MendezRomero, C., Rojas-triana, A., VillalbaGuzman, D., Goldgirsh, K., Rasheed, R., GonzalezJimenez, I., Alvarez-Cabrera, N., Park, S., Murugan, M., Nelson, A. M., Perlin, D. S.
10.1101/2025.07.25.666822 — Posted: 2025-07-25
Immunobridging Analysis of Pemivibart for the Treatement of COVID-19 - A Therapeutic Gap for the Immune Compromised Remains
Holmes, A., Narayan, K., Yalcin, I., Hu, L., Wingertzahn, M.
10.1101/2025.07.23.25332095 — Posted: 2025-07-24
A statistical immune correlates of protection model for predicting efficacy from neutralizing antibody titers to establish immunobridging of monoclonal antibodies for prevention of COVID-19
Yalcin, I., Hu, L., West, B., Narayan, K., Holmes, A., Wingertzahn, M.
10.1101/2025.07.24.25332145 — Posted: 2025-07-24
Quantifying selection bias due to unobserved patients in pharmacoepidemiologic studies of severe COVID-19 cohorts.
Bokern, M., Rentsch, C. T., Quint, J. K., Schultze, A., Douglas, I. J.
10.1101/2025.07.24.25332123 — Posted: 2025-07-24
De novo administration of antiviral monoclonal antibodies against SARS-CoV-2 or influenza using mRNA lipid nanoparticles
Vu, M. N., Neil, J. A., Mackenzie-Kludas, C., Kelly, A., Tan, H.-X., Subbarao, K., Lee, W. S., Wheatley, A. K.
10.1101/2025.07.23.666463 — Posted: 2025-07-24
Characterization of antiviral compounds using Bio-Layer Interferometry
Lorson, Z. C., McFadden, W. M., Neilsen, G., Emanuelli Castaner, A., Slack, R. L., Kirby, K. A., Sarafianos, S. G.
10.1101/2025.07.24.662752 — Posted: 2025-07-24

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).